NPH 29

Drug Profile

NPH 29

Alternative Names: NPH29

Latest Information Update: 07 Jul 2015

Price : $50

At a glance

  • Originator nPharmakon LLC
  • Class Amines; Anti-inflammatories; Benzyl compounds; Pyrazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Hyperpigmentation

Most Recent Events

  • 01 Jul 2015 NPH 29 is available for licensing as of 07 Jul 2015. http://www.npharmakon.com/content/pipeline.html
  • 01 Jul 2015 Efficacy and adverse events data from a clinical study in Hyperpigmentation released by nPharmakon
  • 01 Jun 2015 nPharmakon receives notice of allowance for NPH 29 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top